BIONEWS
Tempus is paying $1.5 billion to fully acquire Personalis, three years after first investing, taking ownership of a blood test that detects trace tumor DNA to monitor cancer recurrence.
Tempus AI is putting roughly $1.5 billion in enterprise value on the table to fully acquire Personalis, the cancer-genomics specialist it first backed in 2023, the companies said on Monday (FierceBiotech, Reuters). The headline figure varies by outlet. Bloomberg put the same deal at $1.7 billion that day (Bloomberg), a gap that reflects different ways of counting equity versus assumed debt rather than a renegotiation.
The asset Tempus is absorbing is Personalis's NeXT Personal test, a liquid biopsy that scans a patient's blood for tiny traces of tumor DNA. The category is known as MRD, short for minimal residual disease, the small amount of cancer that can linger after treatment and drive recurrence. Doctors use MRD tests to monitor whether therapy is working and whether a cancer is returning without a new tissue biopsy each time. Tempus originally invested in Personalis in 2023 and has been co-commercializing NeXT Personal since, the companies' own statements say (Tempus press release). Monday's transaction converts that partnership into outright ownership.
Personalis's preliminary, unaudited second-quarter results provide the only hard operating data point in the source set: $22.4 million in revenue, 10,384 clinical tests delivered, and a roughly 33% sequential jump in test volume from the first quarter (FierceBiotech). Those numbers are the closest the public tape has to a market signal, and Tempus is treating them as the moment to consolidate.
Tempus chief executive Eric Lefkofsky framed the price as a bet on category maturation rather than just an assay acquisition. "The MRD market is large and rapidly growing," he said in the deal announcement, pointing to "clinical adoption and reimbursement momentum" as the underlying driver (Tempus press release). Read against the Q2 volume print, that language tells a specific story. When reimbursement and clinical uptake both move in the same quarter, the cheaper option is rarely the better one.
For Tempus, the strategic logic sits in the data layer more than in the test itself. Tempus already runs a patient-data and AI business serving clinicians and biopharma R&D customers. Folding NeXT Personal in-house means recurrence monitoring feeds the same stack that begins with initial molecular profiling. Personalis gets distribution, Tempus gets a longitudinal molecular feed, and the combined entity can offer biopharma partners a single data pipeline from first diagnosis through long-term monitoring (MobiHealthNews).
The falsifier is sharp. If Tempus wanted only NeXT Personal's assay, a partnership extension at a higher revenue share would have been cheaper than $1.5 billion in enterprise value. The price implies the asset being bought is the longitudinal data layer that comes with owning the test, not the test in isolation. The regulatory record of the combination was filed the same day as a Schedule 425 business-combination communication (SEC filing via StockTitan).
What the deal does not yet settle is the broader MRD market. Lefkofsky's "large and rapidly growing" framing is the only on-the-record market-size language, and no independent oncologist, payer, or competitor has yet commented on the transaction. The next public test of the category will come when Personalis reports audited Q2 results and Tempus updates its full-year guidance to reflect the integration.